""This collaboration with Nuformix allows Oxilio to continue the development of NXP001 as a potential new treatment in the battle against cancer. We are excited by the opportunity of accelerating our science towards our first clinical trials through this collaboration and we look forward to working with the Nuformix team to realise the opportunity"
This was only 24 hours ago remember....17 Nov 2020 08:25
"P2F is continuing to receive enquiries from prospective distributors and purchasers for its viricidal mask and now anticipates that future demand for its mask may outstrip the production line capacity of five million viricidal face masks per month"